



New Scientific Illustrations to Explain the Role of Tau Proteins in Alzheimer’s Disease Launched for World Alzheimer Month

Artwork details emerging scientific research on tau and its role in healthy and aging brains

“Understanding the role that the tau protein plays in the healthy brain, and how pathological tau behaves in an aging brain, is important to advance our collective understanding of Alzheimer’s Disease,” says Claude Wischik, CEO of TauRx, a company with the first tau-based drug to reach Phase 3 clinical trials. “The emerging science explained by these illustrations was previously only available through descriptions published in peer-reviewed, scientific journals. This artwork brings the science to life and makes it more accessible for the broader community seeking to better understand this devastating disease.”

The newly developed scientific illustrations explain in detail the role of the tau protein in the healthy brain to stabilise microtubules for the safe passage of neurotransmitters, and how tau may be impacted by the normal ageing process. The repeat domain of the tau protein binds to lipofuscin in a hairpin formation, recruiting other tau proteins to stack in the same way, and eventually forming tau oligomers, paired helical filaments and tau tangles. This pathological tau is then responsible for damaging neuronal function in a number of ways, spreading through neurons until they cause death of the cells.

Diana Saville, scientific illustrator and Co-Founder of Brain Mind who created the graphics explains, “BrainMind is focused on strengthening the connective tissue between the lab and society. We are delighted to support the Alzheimer’s research community during World Alzheimer’s Month with this growing set of visualization tools, helping scientists to convey important insights from disease mechanisms to emerging therapeutic targets.”

Jean Georges, Executive Director of Alzheimer Europe, welcomed the educational material and the information on the Lucidity trial: “People living with Alzheimer’s disease, their families and carers, as well as Alzheimer’s associations are closely following research developments in the hope of better treatment and

TauRx Pharmaceuticals Ltd. 3, Shenton Way, #21-04, Shenton House, Singapore 068805, Republic of Singapore
TauRx Therapeutics Ltd. 3, Shenton Way, #21-04, Shenton House, Singapore 068805, Republic of Singapore
TauRx Research Facility Liberty Building, Foresterhill Road, Aberdeen AB25 2ZP, UK

For further information visit www.taurx.com



prevention possibilities. Alzheimer Europe aims to provide easy-to-understand information on ongoing clinical trials and we are therefore very grateful to TauRx for presenting their phase III program to our members. The educational material and visuals launched at our meeting will be very useful in explaining the important role of tau in the development of Alzheimer's disease to a non-scientific audience".

The scientific illustrations were launched on 10 September, at a meeting organised by Alzheimer Europe and attended by 24 of its national member organisations and will soon be publicly available on www.TargetingTau.com. BrainMind developed the illustrations through an educational grant from TauRx, with an aim to explain to doctors and their patients how abnormal tau aggregation affects the brain and how this could be treated.

"We all dream of the day when a treatment can be introduced early enough in the disease cascade to prevent or slow down the tragedy that AD represents for all," says Professor Wischik. "Explaining this science is an important step in bringing a transformation treatment to patients around the world."

About Alzheimer Europe

Alzheimer Europe is the umbrella organisation of national Alzheimer associations and currently has 39 member organisations in 35 European countries. The mission statement of the organisation is to change perceptions, practice, and policy to ensure equal access of people with dementia to a high level of care services and treatment options.

Email: info@alzheimer-europe.org

Website: www.alzheimer-europe.org

About BrainMind

BrainMind is a not-for-profit organisation with a mission to support and cultivate the most important and impactful ideas in brain science. Co-founder and CCO Diana Saville is an expert in creative communication of complex scientific concepts.

TauRx Pharmaceuticals Ltd. 3, Shenton Way, #21-04, Shenton House, Singapore 068805, Republic of Singapore
TauRx Therapeutics Ltd. 3, Shenton Way, #21-04, Shenton House, Singapore 068805, Republic of Singapore
TauRx Research Facility Liberty Building, Foresterhill Road, Aberdeen AB25 2ZP, UK

For further information visit www.taurx.com



Email: dsaville@brainmind.org

Website: www.brainmind.org

About TauRx Therapeutics Ltd

TauRx's goal in providing these materials first to Alzheimer Europe and its members, is to help people understand how its lead compound, hydromethylthionine, works and how it might benefit the patients currently enrolling in its ongoing clinical trial (Lucidity). Hydromethylthionine is currently the only drug for AD in a phase 3 clinical trial. It has already been tested in over 2000 patients in phase 3 trials in both mild to moderate AD, and behavioural variant Fronto-Temporal Dementia. Recently published population-based analyses looking at how blood levels relate to treatment response showed similar concentration-dependent pharmacological activity on clinical decline and brain atrophy in both diseases. The predicted optimal dose in AD was found to be 16 mg/day as monotherapy. The Lucidity trial aims to confirm this result by comparing hydromethylthionine against placebo in 450 patients. Results are expected to be available by mid-2022.

TauRx Therapeutics Ltd is a member of the TauRx Pharmaceuticals group, which is developing technology spun-out from the University of Aberdeen, Scotland. The company was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases. The company's protein aggregation inhibitor, hydromethylthionine, targets aggregates of abnormal fibres of tau and TDP-43 proteins that form inside nerve cells in the brain. TauRx's headquarters are in Singapore and its primary research facilities are based in Aberdeen.

Media Contacts

Email: Taurxpress@syneoshealth.com

Website: <http://www.taurx.com>

30th September 2020

TauRx Pharmaceuticals Ltd. 3, Shenton Way, #21-04, Shenton House, Singapore 068805, Republic of Singapore
TauRx Therapeutics Ltd. 3, Shenton Way, #21-04, Shenton House, Singapore 068805, Republic of Singapore
TauRx Research Facility Liberty Building, Foresterhill Road, Aberdeen AB25 2ZP, UK

For further information visit www.taurx.com